These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24305093)

  • 1. [Current status and future directions of chemotherapy for pancreatic cancer].
    Furuse J
    Nihon Shokakibyo Gakkai Zasshi; 2013 Dec; 110(12):2060-5. PubMed ID: 24305093
    [No Abstract]   [Full Text] [Related]  

  • 2. [The progress of chemotherapy for advanced pancreatic cancer].
    Ioka T; Katayama K; Ashida R; Takahashi H; Teshima T; Sakon M
    Nihon Shokakibyo Gakkai Zasshi; 2015 Dec; 112(12):2119-26. PubMed ID: 26638783
    [No Abstract]   [Full Text] [Related]  

  • 3. First-line treatment for advanced pancreatic cancer.
    Kothari N; Saif MW; Kim R
    JOP; 2013 Mar; 14(2):129-32. PubMed ID: 23474553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-surgical treatment for pancreatic cancer].
    Okusaka T; Ueno H; Ikeda M; Morizane C
    Nihon Shokakibyo Gakkai Zasshi; 2006 Apr; 103(4):391-7. PubMed ID: 16629457
    [No Abstract]   [Full Text] [Related]  

  • 5. [Adjuvant gemcitabine plus S-1 chemotherapy for pancreatic cancer after surgical resection - outcomes and future perspectives].
    Murakami Y; Uemura K; Sudo T
    Nihon Shokakibyo Gakkai Zasshi; 2011 Oct; 108(10):1661-9. PubMed ID: 21971141
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?
    Yamada D; Kobayashi S; Takahashi H; Iwagami Y; Akita H; Asukai K; Shimizu J; Yamada T; Tanemura M; Yokoyama S; Tsujie M; Asaoka T; Takeda Y; Morimoto O; Tomokuni A; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jul; 31(7):4702-4703. PubMed ID: 38722422
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
    Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
    Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
    Yamauchi J; Kanai M; Matsumoto S; Nishimura T; Yazumi S; Kami K; Kawaguchi Y; Yasuda H; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Fukushima M; Doi R; Chiba T
    Pancreas; 2008 Apr; 36(3):327-8. PubMed ID: 18362852
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
    Abe K; Uwagawa T; Haruki K; Takano Y; Onda S; Sakamoto T; Gocho T; Yanaga K
    Anticancer Res; 2018 Apr; 38(4):2369-2375. PubMed ID: 29599363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent updates on the role of chemotherapy in pancreatic cancer.
    Burris HA
    Semin Oncol; 2005 Aug; 32(4 Suppl 6):S1-3. PubMed ID: 16143160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy of pancreatic carcinoma].
    Lutz MP
    Praxis (Bern 1994); 2005 Jun; 94(22):933-5. PubMed ID: 15986638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer: will incremental advances begin to make a difference?
    Holzman DC
    J Natl Cancer Inst; 2010 Dec; 102(24):1821-3. PubMed ID: 21139096
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
    Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
    Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
    Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada Y; Kumamoto T; Endo I
    World J Surg; 2020 Aug; 44(8):2752-2760. PubMed ID: 32291503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [FOLFIRINOX, nab-paclitaxel + gemcitabine].
    Shimizu S
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():405-8. PubMed ID: 25857057
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatments of pancreatic cancer from the standpoint of medical oncology].
    Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):997-1001. PubMed ID: 17637534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What options are available for refractory pancreatic cancer?
    Choi M; Kim R; Saif MW
    JOP; 2012 Mar; 13(2):163-5. PubMed ID: 22406591
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.